Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Reply to Bisol: Critical review and recommendations for enhancement of the article on novel neurosteroid therapeutics for postpartum depression


This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, Deligiannidis KM, Rubinow DR, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet 2018;392:1058–70.

    Article  CAS  PubMed  Google Scholar 

  2. Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014;13:153–60.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Johannsen BMW, Larsen JT, Laursen TM, Bergink V, Meltzer-Brody S, Munk-Olsen T. All-cause mortality in women with severe postpartum psychiatric disorders. Am J Psychiatry. 2016;173:635–42.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Patterson R, Krohn H, Richardson E, Kimmel M, Meltzer-Brody S. A brexanolone treatment program at an academic medical center: patient selection, 90-day posttreatment outcomes, and lessons learned. J Acad Consult Liaison Psychiatry 2022;63:14–22.

    Article  PubMed  Google Scholar 

Download references


SM-B has previously received research funding as an Investigator to UNC from Sage Therapeutics for other projects. SM-B has received consulting fees from EmbarckNeuro, Modern Health, Neuroscience Education Institute and Web MD. Past work reflected here was partially funded by a grant from the Foundation of Hope, Raleigh, NC and support from the UNC School of Medicine, Chapel Hill, NC.

Author information

Authors and Affiliations



Riah Patterson: drafting the work, and substantial contributions to the conception or design of the work; the acquisition, analysis, and interpretation of data for the work. Samantha Meltzer-Brody: drafting the work or revising it critically for important intellectual content and final approval of the version to be published. Both authors agree to be accountable for all aspects of the work.

Corresponding author

Correspondence to Riah Patterson.

Ethics declarations

Competing interests

The authors declare no potential conflicts of interest. Per above, SM-B has served as the academic PI for the brexanolone clinical trials and received research funding to UNC for these studies.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patterson, R., Meltzer-Brody, S. Reply to Bisol: Critical review and recommendations for enhancement of the article on novel neurosteroid therapeutics for postpartum depression. Neuropsychopharmacol. 49, 1063–1064 (2024).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links